Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Cantini, Luca; Giglio, Enrica; Bittoni, Alessandro; Lanese, Andrea; Crocetti, Sonia; Pecci, Federica; Copparoni, Cecilia; Meletani, Tania; Lenci, E.; Lupi, Alessio; Baleani, Maria Giuditta; Berardi, Rossana

doi:10.3390/cancers12102724

Cited by 5 publications

(5 citation statements)

References 119 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review reported that users of SSRIs and other antidepressants did not experience any notable effect on the risk of colon cancer. Moreover, no clear evidence of either beneficial or harmful association was found between antidepressant treatment and cancer, including colon cancer [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

“…Notably, no evidence was found in humans of either a beneficial or a harmful association between antidepressant treatment and cancer, including breast cancer and colon cancer [ 33 , 37 , 38 ]. If, however, the response to SSRIs in humans is indeed similar to that of rodents, then these results indicate that special care has to be taken when prescribing sertraline or citalopram as antidepressants to cancer patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level

Taler

Gil-Ad

Brener

et al. 2022

IJMS

View full text Add to dashboard Cite

Some selective serotonin reuptake inhibitors (SSRIs), primarily sertraline, demonstrate anti-proliferative activity in malignant cell-lines and in xenografted mouse models of colorectal tumor. There is, however, a paucity of comparative studies on the anti-tumor effects of SSRIs. We compared the in vitro and in vivo effects of sertraline and citalopram on murine 4T1 breast cancer. Grafted mice were used to determine the rate of tumor growth and survival as well as the impact of stress and antidepressant treatment on tumor progression and mortality and on pro-inflammatory cytokines. Sertraline, in the micromolar range, but not citalopram, induced a significant in vitro concentration-dependent inhibition of murine 4T1 cell proliferation and splenocyte viability. In contrast, sertraline (10 mg/kg/d), enhanced in vivo tumor growth. Contrary to the study’s hypothesis, chronic mild stress did not modify tumor growth in grafted mice. The in vitro effects of sertraline on tumor growth seem to be the opposite of its in vivo effects. The impact of sertraline treatment on humans with breast cancer should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level

Taler

Gil-Ad

Brener

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Drug repurposing or repositioning involves using approved drugs for conditions different from their original indication [13][14][15]. Several drugs have acquired additional use in the past years and have been reintroduced into practice fueled by this phenomenon.…”

Section: Repurposing Approved Drugs In Colon Cancermentioning

confidence: 99%

Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing

Yibirin

Oliveira-Gomes²,

Machaalani

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.

show abstract

“…Appropriate management through continued use of statins may lead to better results in patients [ 21 ]; however, statin use may have different effects in patients with dyslipidemia and dyslipidemia patients with cancer. In this study, we evaluated the effects of continued use of post-diagnostic statins and the doses of these drugs on mortality in dyslipidemia patients with or without GI cancer.…”

Section: Introductionmentioning

confidence: 99%

Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer

Han

Kim

2021

JCM

View full text Add to dashboard Cite

Background: Statins play a role in lowering serum cholesterol and are known to have pleiotropic effects in a variety of diseases, including cancer. Despite the beneficial effects of statins in dyslipidemia patients, the treatment rate for dyslipidemia in Korea remains low, and evidence supporting the continued use of statins is lacking. The purpose of this study was to evaluate the effect of continued statin use and dosage on patient mortality after diagnosis of dyslipidemia and gastrointestinal (GI) cancer. Methods: We used data from the National Health Insurance Sampling (NHIS) cohort to evaluate patients diagnosed with dyslipidemia from 2002 to 2015. A total of 901 GI cancer patients with dyslipidemia and 62,727 non-cancer dyslipidemia patients were included in the study. During the study period, each patient’s medication possession ratio (MPR) after diagnosis was evaluated as a measure of continued statin use. Statin dosage was measured based on a defined daily dose (DDD). Finally, we used Cox-proportional hazard ratios to identify associations between the continual use of statins and mortality in patients with dyslipidemia and GI cancer. Results: In our study, mortality decreased with increasing MPR and reached significance in MPRs exceeding 50% for GI cancer patients and 75% for dyslipidemia patients compared to patients that did not use statins. Moreover, patients with high MPRs had significantly reduced 5-year mortality compared to non-users, and cause-specific mortality analyses revealed that high MPR was associated with decreased colorectal cancer death. We did not find a significant dose–response relationship between statins and mortality. Conclusion: Our findings suggest that continued statin use after diagnosis is associated with reduced patient mortality. Altogether, these results support the continued use of statins in dyslipidemia patients with and without GI cancer and highlight the importance of patient education by healthcare providers.

show abstract

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing

Cited by 5 publications

References 119 publications

Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level

Complex Effects of Sertraline and Citalopram on In Vitro Murine Breast Cancer Proliferation and on In Vivo Progression and Anxiety Level

Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing

Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer

Contact Info

Product

Resources

About